Quick search:
| Result | Content | Outlet | Published | Research |
|---|---|---|---|---|
| Result | Content | Outlet | Published | Research |
| 1 | Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022 | GlobeNewswire | 30 days ago | |
| 2 | Sanofi's Sarclisa Scores In Myeloma But Is Still In Darzalex's Shadow | Scrip | 2 days ago | |
| 3 | Darzalex: Side effects and what to do about them | Medical News Today | 2 months ago | |
| 4 | Darzalex for multiple myeloma: Uses, how it works, and more | Medical News Today | 9 months ago | |
| 5 | Darzalex Dosage: Form, Strengths, How to Use, and More | Healthline | 3 months ago | |
| 6 | Genmab Announces Financial Results for the First Quarter of 2022 | BioSpace | 8 days ago | |
| 7 | Darzalex Faspro: Side effects and how to manage them | Medical News Today | 3 months ago | |
| 8 | NICE Recommends Darzalex in Combination with Velcade to Treat Multiple Myeloma | Pharmaceutical Technology Magazine | 4 months ago | |
| 9 | US FDA Approves DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse | PR Newswire | 6 months ago | |
| 10 | NICE rebuffs J&J's Darzalex price for newly diagnosed myeloma but leaves negotiation door open | FiercePharma | 9 months ago | |
| 11 | Darzalex Faspro Combo Therapy for Myeloma Patients Approved by FDA | Myeloma Research News | 5 months ago | |
| 12 | Genmab Announces Multiple Abstracts to Be Presented at the European Hematology Association (EHA) Annual Congress | Valdosta Daily Times | 7 days ago | |
| 13 | New Clinical and Real-World Data Support Use of DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma | Business Wire | 5 months ago | |
| 14 | FDA's Approval of Subcutaneous Darzalex-Based Regimen Adds Another 'Tool in the Toolbox' to Treat Pretreated Myeloma | Curetoday.com | 5 months ago | |
| 15 | ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myeloma | FiercePharma | 5 months ago | |
| 16 | Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives | Curetoday.com | 4 months ago | |
| 17 | FDA approves Darzalex Faspro for use in relapsed multiple myeloma | Healio | 10 months ago | |
| 18 | NICE says 'yes' to Darzalex for relapsed and refractory MM | The Pharma Letter | 2 months ago | |
| 19 | J&J scores one-two royalty punch against Genmab in blockbuster Darzalex fight | FiercePharma | 1 month ago | |
| 20 | Xbrane Seeks to Bring Keytruda and Darzalex Biosimilars to Market | The Center for Biosimilars | 5 months ago | |
| 21 | Johnson & Johnson suspends COVID-19 vaccine sales forecast | New York Post | 30 days ago | |
| 22 | Johnson & Johnson Stock: A Rare Bright Spot in the Market | InvestorPlace | 5 days ago | |
| 23 | Darzalex SC (Daratumumab) Drug / Medicine Information | News-Medical.Net | 12 months ago | |
| 24 | DARZALEX® (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma | Business Wire | 11 months ago | |
| 25 | Pharmacist Medication Insights: Darzalex Faspro for Multiple Myeloma | Pharmacy Times | 9 months ago | |
| 26 | J&J's Darzalex shows 'significant' survival benefit in newly diagnosed multiple myeloma | PMLiVE | 11 months ago | |
| 27 | Sanofi Challenges J&J's Darzalex With Blackstone Pact For SC Sarclisa | Scrip | 2 months ago | |
| 28 | Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe | Business Wire | 12 months ago | |
| 29 | Darzalex (daratumumab): Side effects, cost, dosage, and more | Medical News Today | 2 years ago | |
| 30 | J&J defends Darzalex with FDA approval for faster dosing | - pharmaphorum | 2 years ago | |
| 31 | Darzalex (Daratumumab) | Myeloma Research News | 2 years ago | |
| 32 | Non-genetic amyloidosis lives again, thanks to Darzalex and Astra | Vantage | 8 months ago | |
| 33 | FDA Approves Darzalex Faspro as Injection Therapy for Multiple Myeloma | Myeloma Research News | 2 years ago | |
| 34 | HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | Marketscreener.com | 8 days ago | |
| 35 | With subcut Darzalex driving growth, Halozyme eyes role for drug delivery tech in cell therapies | FiercePharma | 6 months ago | |
| 36 | New DARZALEX® (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma | BioSpace | 1 year ago | |
| 37 | This Dividend King Just Joined an Exclusive Club -- Here's Why the Stock Is a Buy | The Motley Fool | 8 days ago | |
| 38 | Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submission | - pharmaphorum | 2 years ago | |
| 39 | Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Regimen After First or Subsequent Relapse in Multiple Myeloma | BioSpace | 1 year ago | |
| 40 | Another Win For Darzalex as FDA Approves Combination Treatment For Multiple Myeloma | BioSpace | 3 years ago | |
| 41 | Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether | Forbes | 17 hours ago | |
| 42 | US Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma | PR Newswire | 2 years ago | |
| 43 | Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma | OncLive | 4 months ago | |
| 44 | J&J's Darzalex Faspro is first US therapy for rare blood disorder | - pharmaphorum | 1 year ago | |
| 45 | FDA Approves Darzalex Triple Combo for Advanced Multiple Myeloma | Myeloma Research News | 2 years ago | |
| 46 | Janssen Submits Applications in US and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patie | PR Newswire | 2 years ago | |
| 47 | US FDA Approves New DARZALEX® (daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma | PR Newswire | 2 years ago | |
| 48 | Sanofi's Sarclisa forays into Darzalex's new territory with FDA nod in earlier myeloma | FiercePharma | 1 year ago | |
| 49 | For Myeloma, Injectable Darzalex Faspro Gets CHMP Nod for EU Approval | Myeloma Research News | 2 years ago | |
| 50 | FDA Approves Darzalex for New Multiple Myeloma Indication | BioSpace | 3 years ago | |
| 51 | Top Orphan Drugs Rare Disease Therapies 2021 | BioSpace | 13 hours ago | |
| 52 | European Commission Approves Darzalex® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible | Business Wire | 2 years ago | |
| 53 | Sanofi builds case for Sarclisa, challenging J&J's Darzalex | - pharmaphorum | 2 years ago | |
| 54 | Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports | Myeloma Research News | 2 years ago | |
| 55 | Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab) | GlobeNewswire | 1 year ago | |
| 56 | Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma | Curetoday.com | 5 months ago | |
| 57 | Three-Drug Combo Meets 'Gold Standard' Overall Survival for Older Patients with Multiple Myeloma | Curetoday.com | 6 months ago | |
| 58 | Johnson & Johnson Reports Q1 2022 Results | Johnson & Johnson | 30 days ago | |
| 59 | FDA approves Darzalex-based combination for first-line multiple myeloma treatment | Healio | 3 years ago | |
| 60 | New Under-the-skin Darzalex Formulation Approved in EU | Myeloma Research News | 2 years ago | |
| 61 | European Commission Grants Marketing Authorisation for DARZALEX® (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications | Business Wire | 2 years ago | |
| 62 | J&J's Darzalex Proves Effective in Yet Another Multiple Myeloma Indication | PharmaLive | 2 years ago | |
| 63 | Genmab/Janssen's Darzalex combo hits the mark in phase 3 study | PharmaTimes | 2 years ago | |
| 64 | J&J's next-gen Darzalex sparks drug delivery royalties battle | FiercePharma | 2 years ago | |
| 65 | Multiple Myeloma: Darzalex Triple Combo Therapy Approved by FDA | Myeloma Research News | 3 years ago | |
| 66 | FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro | Regulatory Focus | 10 months ago | |
| 67 | Janssen's Darzalex approved in EU for newly-diagnosed multiple myeloma | - pharmaphorum | 2 years ago | |
| 68 | Recap: Treatment Options in Transplant-Eligible and -Ineligible Multiple Myeloma | Cancer Network | 4 days ago | |
| 69 | Johnson & Johnson: How Does Darzalex Compare To Other Multiple Myeloma Drugs? | Forbes | 3 years ago | |
| 70 | Sarclisa Extends Survival in RRMM, Long-term Phase 3 Trial Data Shows | Myeloma Research News | 2 months ago | |
| 71 | Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties | BioSpace | 2 years ago | |
| 72 | Type of Multiple Myeloma May Affect Responses to Darzalex, Study Finds | Myeloma Research News | 5 years ago | |
| 73 | Positive results for Darzalex, Jakavi to be reported at ASH | Managed Healthcare Executive | 1 year ago | |
| 74 | Kyprolis: Side Effects, Uses, Dosage, and More | Healthline | 2 months ago | |
| 75 | FDA Approves Darzalex Faspro Formulation for Multiple Myeloma | Clinical Oncology News | 2 years ago | |
| 76 | Despite legal troubles, Johnson & Johnson is in the financial driver's seat for 2022 and beyond, CFO says | FiercePharma | 7 months ago | |
| 77 | Relapsed, Refractory Myeloma Patients Benefit From Darzalex Faspro Combo in Phase 3 Trial | Myeloma Research News | 2 years ago | |
| 78 | Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan | GlobeNewswire | 3 years ago | |
| 79 | Triple Therapy with Darzalex Improves Pain, Quality of Life in Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation | Curetoday.com | 1 year ago | |
| 80 | J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price | FiercePharma | 7 years ago | |
| 81 | Sanofi gets first OK for isatuximab for myeloma, challenging J&J's Darzalex | - pharmaphorum | 2 years ago | |
| 82 | Janssen Announces Health Canada Approval of DARZALEX®* SC, a New Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma Français | Canada NewsWire | 2 years ago | |
| 83 | Subcutaneous Formulation of Daratumumab Approved for Multiple Myeloma | Monthly Prescribing Reference | 2 years ago | |
| 84 | Bio-Rad Introduces Anti-Daratumumab Antibodies | The Scientist | 3 months ago | |
| 85 | 'Very Promising': Daratumumab as Part of Multiple Myeloma Care | Medpage Today | 1 year ago | |
| 86 | Multiple Myeloma Can Be Treated with Darzalex as Split Dose Over Consecutive Days, FDA Agrees | Myeloma Research News | 3 years ago | |
| 87 | Subcutaneous Daratumumab Plus VCd Approved in Canada for Newly Diagnosed Light Chain Amyloidosis | OncLive | 1 year ago | |
| 88 | Multiple Myeloma Combo Therapy That Includes Darzalex Wins FDA Approval | Myeloma Research News | 5 years ago | |
| 89 | Janssen Announces Health Canada Approval of DARZALEX®* Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma | Canada NewsWire | 1 year ago | |
| 90 | Darzalex Combo Increases Response Rates in Newly Diagnosed... | Myeloma Research News | 3 years ago | |
| 91 | Janssen looks to expand Darzalex in Europe | PMLiVE | 3 years ago | |
| 92 | Short Interest in Genmab A/S (OTCMKTS:GNMSF) Rises By 92.6% | Defense World | 3 days ago | |
| 93 | Empliciti’s front-line flop underlines Darzalex’s dominance | Vantage | 2 years ago | |
| 94 | Janssen, Genmab Partner on Follow-On to Darzalex for Multiple Myeloma, Diffuse Large B-Cell Lymphoma | Genetic Engineering & Biotechnology News | 3 years ago | |
| 95 | Daratumumab Plus Lenalidomide/Dexamethasone Combination Demonstrated Survival Benefit for Newly Diagnosed Multiple Myeloma | Cancer Network | 8 months ago | |
| 96 | Why Darzalex Is Growing Faster Than Revlimid, Particularly Outside The U.S. | Seeking Alpha | 4 years ago | |
| 97 | Ease of Use With Subcutaneous Daratumumab Supplants the Intravenous Formulation as Standard of Care Across Settings in Myeloma | Targeted Oncology | 2 years ago | |
| 98 | Darzalex EU nod marks first newly diagnosed MM treatment in six years | PharmaTimes | 2 years ago | |
| 99 | Sanofi keeps nipping at J&J's heels as Sarclisa notches new FDA approval in multiple myeloma | Endpoints News | 1 year ago | |
| 100 | Part 1: Debating Primary Therapy for Transplant-Eligible Multiple Myeloma | Targeted Oncology | 1 month ago |